Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Neuroblastoma with intracerebral metastases and the need for neurosurgery: a single-center experience.

Fleck S, Marx S, Bobak C, Richter V, Nowak S, Rafaee EE, Siebert N, Ehlert K, Schroeder HWS, Lode HN.

J Neurosurg Pediatr. 2019 Oct 11:1-6. doi: 10.3171/2019.7.PEDS19143. [Epub ahead of print]

PMID:
31604318
2.

Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: A case report.

Lode HN, Henze G, Siebert N, Ehlert K, Barthlen W.

Medicine (Baltimore). 2019 Aug;98(34):e16752. doi: 10.1097/MD.0000000000016752.

3.

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C.

Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.

PMID:
30879952
4.

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.

Marx M, Zumpe M, Troschke-Meurer S, Shah D, Lode HN, Siebert N.

PLoS One. 2018 Nov 19;13(11):e0207320. doi: 10.1371/journal.pone.0207320. eCollection 2018.

5.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN.

Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12.

PMID:
30442501
6.

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Siebert N, Troschke-Meurer S, Marx M, Zumpe M, Ehlert K, Gray J, Garaventa A, Manzitti C, Ash S, Klingebiel T, Beck J, Castel V, Valteau-Couanet D, Loibner H, Ladenstein R, Lode HN.

Cancers (Basel). 2018 Oct 17;10(10). pii: E387. doi: 10.3390/cancers10100387.

7.

Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN.

Pediatr Blood Cancer. 2018 Jun;65(6):e26967. doi: 10.1002/pbc.26967. Epub 2018 Jan 19.

PMID:
29350486
8.

Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.

Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P.

Biol Blood Marrow Transplant. 2018 May;24(5):1005-1012. doi: 10.1016/j.bbmt.2017.12.805. Epub 2018 Jan 4.

9.

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Lodrini M, Sprüssel A, Astrahantseff K, Tiburtius D, Konschak R, Lode HN, Fischer M, Keilholz U, Eggert A, Deubzer HE.

Oncotarget. 2017 Jul 7;8(49):85234-85251. doi: 10.18632/oncotarget.19076. eCollection 2017 Oct 17.

10.

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN.

Oncoimmunology. 2017 Jul 5;6(10):e1343775. doi: 10.1080/2162402X.2017.1343775. eCollection 2017.

11.

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN.

MAbs. 2018 Jan;10(1):55-61. doi: 10.1080/19420862.2017.1402997. Epub 2017 Dec 5.

12.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.

13.

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN.

Oncoimmunology. 2016 Sep 26;5(11):e1235108. doi: 10.1080/2162402X.2016.1235108. eCollection 2016.

14.

GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent.

Winkler A, Kietz S, Bahlmann H, Jafarzade G, Lode HN, Heckmann M.

Clin Case Rep. 2016 Jul 20;4(8):816-9. doi: 10.1002/ccr3.616. eCollection 2016 Aug.

15.

The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study.

Lange AE, Thyrian JR, Wetzka S, Flessa S, Hoffmann W, Zygmunt M, Fusch C, Lode HN, Heckmann M.

BMC Pregnancy Childbirth. 2016 Jul 29;16(1):197. doi: 10.1186/s12884-016-0966-0.

16.

Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

Eger C, Siebert N, Seidel D, Zumpe M, Jüttner M, Brandt S, Müller HP, Lode HN.

PLoS One. 2016 Mar 11;11(3):e0150479. doi: 10.1371/journal.pone.0150479. eCollection 2016.

17.

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN.

MAbs. 2016;8(3):604-16. doi: 10.1080/19420862.2015.1130196. Epub 2016 Jan 19.

18.

Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.

Fest S, Soldati R, Christiansen NM, Zenclussen ML, Kilz J, Berger E, Starke S, Lode HN, Engel C, Zenclussen AC, Christiansen H.

Int J Cancer. 2016 Apr 15;138(8):2030-42. doi: 10.1002/ijc.29933. Epub 2015 Dec 12.

19.

Mutational dynamics between primary and relapse neuroblastomas.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH.

Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.

PMID:
26121086
20.

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.

Stermann A, Huebener N, Seidel D, Fest S, Eschenburg G, Stauder M, Schramm A, Eggert A, Lode HN.

Cancer Immunol Immunother. 2015 Oct;64(10):1215-27. doi: 10.1007/s00262-015-1733-1. Epub 2015 Jun 16.

PMID:
26076666
21.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.

Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.

PMID:
25711293
22.

Febrile ulceronecrotic Mucha-Habermann disease following suspected hemorrhagic chickenpox infection in a 20-month-old boy.

Lode HN, Döring P, Lauenstein P, Hoeger P, Dombrowski F, Bruns R.

Infection. 2015 Oct;43(5):583-8. doi: 10.1007/s15010-015-0726-5. Epub 2015 Jan 28.

PMID:
25627543
23.

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.

Siebert N, Seidel D, Eger C, Jüttner M, Lode HN.

PLoS One. 2014 Sep 16;9(9):e107692. doi: 10.1371/journal.pone.0107692. eCollection 2014.

24.

Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.

Siebert N, Eger C, Seidel D, Jüttner M, Lode HN.

J Immunol Methods. 2014 May;407:108-15. doi: 10.1016/j.jim.2014.04.001. Epub 2014 Apr 12.

PMID:
24727144
25.

Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood.

Chowdhury F, Lode HN, Cragg MS, Glennie MJ, Gray JC.

Cancer Immunol Immunother. 2014 Jun;63(6):559-69.

PMID:
24658837
26.

[Incidence and duration of therapy of pathological hip findings in U2 and U3 examinations (SNiP study)].

Lange A, Lange J, Thyrian R, Haas JP, Ekkernkamp A, Merk H, Hoffmann W, Lode HN.

Orthopade. 2014 Feb;43(2):129-35. doi: 10.1007/s00132-013-2200-3. German.

PMID:
24464331
27.

Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.

Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, Lode HN.

J Immunol Methods. 2013 Dec 15;398-399:51-9. doi: 10.1016/j.jim.2013.09.008. Epub 2013 Sep 18.

PMID:
24055592
28.

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, Michon J, Garaventa A, Lode HN.

MAbs. 2013 Sep-Oct;5(5):801-9. doi: 10.4161/mabs.25215. Epub 2013 May 31.

29.

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response.

Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, Reker D, Brandt S, Mueller HP, Helm C, Siebert N.

Cancer Immunol Immunother. 2013 Jun;62(6):999-1010. doi: 10.1007/s00262-013-1413-y. Epub 2013 Apr 17.

PMID:
23591980
30.

Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma.

Berger E, Soldati R, Huebener N, Hohn O, Stermann A, Durmus T, Lobitz S, Zenclussen AC, Christiansen H, Lode HN, Fest S.

Cancer Lett. 2013 May 1;331(2):167-73. doi: 10.1016/j.canlet.2012.12.026. Epub 2013 Jan 18.

PMID:
23337288
31.

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.

Shibina A, Seidel D, Somanchi SS, Lee DA, Stermann A, Maurer BJ, Lode HN, Reynolds CP, Huebener N.

J Mol Med (Berl). 2013 Apr;91(4):459-72. doi: 10.1007/s00109-012-0958-0. Epub 2012 Sep 30.

PMID:
23052481
32.

Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.

Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, Prenter S, Harvey H, Domingo-Fernández R, Bray IM, Piskareva O, Ng CY, Lode HN, Davidoff AM, Stallings RL.

PLoS One. 2012;7(5):e38129. doi: 10.1371/journal.pone.0038129. Epub 2012 May 25.

33.

Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis.

Eschenburg G, Eggert A, Schramm A, Lode HN, Hundsdoerfer P.

Cancer Res. 2012 May 15;72(10):2645-56. doi: 10.1158/0008-5472.CAN-11-4072. Epub 2012 Apr 9.

34.

Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.

Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, Singer M, Geffers C, Querfeld U.

J Hosp Infect. 2012 Apr;80(4):304-9. doi: 10.1016/j.jhin.2012.01.003. Epub 2012 Feb 18.

PMID:
22342714
35.

A new development of triterpene acid-containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia.

Delebinski CI, Jaeger S, Kemnitz-Hassanin K, Henze G, Lode HN, Seifert GJ.

Cell Prolif. 2012 Apr;45(2):176-87. doi: 10.1111/j.1365-2184.2011.00801.x. Epub 2012 Jan 3.

PMID:
22221251
36.

Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments.

Soldati R, Berger E, Zenclussen AC, Jorch G, Lode HN, Salatino M, Rabinovich GA, Fest S.

Int J Cancer. 2012 Sep 1;131(5):1131-41. doi: 10.1002/ijc.26498. Epub 2011 Dec 5.

37.

Acupuncture for treatment of acute vomiting in children with gastroenteritis and pneumonia.

Anders EF, Findeisen A, Lode HN, Usichenko TI.

Klin Padiatr. 2012 Mar;224(2):72-5. doi: 10.1055/s-0031-1283144. Epub 2011 Aug 3.

PMID:
21815129
38.

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS.

J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x.

39.

DNA vaccination: using the patient's immune system to overcome cancer.

Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN.

Clin Dev Immunol. 2010;2010:169484. doi: 10.1155/2010/169484. Epub 2010 Dec 16. Review.

40.

Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma.

Bleeke M, Fest S, Huebener N, Landgraf C, Schraven B, Gaedicke G, Volkmer R, Lode HN.

Eur J Cancer. 2009 Nov;45(16):2915-21. doi: 10.1016/j.ejca.2009.07.026. Epub 2009 Aug 18.

PMID:
19695868
41.

Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma.

Huebener N, Fest S, Hilt K, Schramm A, Eggert A, Durmus T, Woehler A, Stermann A, Bleeke M, Baykan B, Weixler S, Gaedicke G, Lode HN.

Mol Cancer Ther. 2009 Aug;8(8):2392-401. doi: 10.1158/1535-7163.MCT-09-0107. Epub 2009 Aug 11.

42.

Eradication of CD19+ leukemia by targeted calicheamicin θ.

Bernt KM, Prokop A, Huebener N, Gaedicke G, Wrasidlo W, Lode HN.

Bioconjug Chem. 2009 Aug 19;20(8):1587-94. doi: 10.1021/bc900128h. Epub 2009 Jul 2.

PMID:
19572629
43.

Survivin minigene DNA vaccination is effective against neuroblastoma.

Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, Baykan B, Zenclussen AC, Michalsky E, Jaeger IS, Preissner R, Hohn O, Weixler S, Gaedicke G, Lode HN.

Int J Cancer. 2009 Jul 1;125(1):104-14. doi: 10.1002/ijc.24291.

44.

A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity.

Huebener N, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y, Gaedicke G, Lode HN.

Mol Cancer Ther. 2008 Jul;7(7):2241-51. doi: 10.1158/1535-7163.MCT-08-0109.

45.

Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro.

Seifert G, Jesse P, Laengler A, Reindl T, Lüth M, Lobitz S, Henze G, Prokop A, Lode HN.

Cancer Lett. 2008 Jun 18;264(2):218-28. doi: 10.1016/j.canlet.2008.01.036. Epub 2008 Mar 7.

PMID:
18314258
46.

Supporting the hypothesis of pregnancy as a tumor: survivin is upregulated in normal pregnant mice and participates in human trophoblast proliferation.

Fest S, Brachwitz N, Schumacher A, Zenclussen ML, Khan F, Wafula PO, Casalis PA, Fill S, Costa SD, Mor G, Volk HD, Lode HN, Zenclussen AC.

Am J Reprod Immunol. 2008 Jan;59(1):75-83.

PMID:
18154598
47.
48.

Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia.

Lode HN, Krings G, Schulze-Neick I, Dähmlow S, Schroeder U, Bonnet R, DaPalma J, Luck W, Strauss G, Berger F, Gaedicke G.

J Pediatr Hematol Oncol. 2007 Mar;29(3):173-7.

PMID:
17356397
49.

Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.

Zeng Y, Huebener N, Fest S, Weixler S, Schroeder U, Gaedicke G, Xiang R, Schramm A, Eggert A, Reisfeld RA, Lode HN.

Cancer Res. 2007 Mar 1;67(5):2331-8.

50.

Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.

Fest S, Huebener N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Förster-Wald E, Jensen-Jarolim E, Lode HN.

Cancer Res. 2006 Nov 1;66(21):10567-75.

Supplemental Content

Support Center